Fresenius Medcare: UBS downgrades stock

(CercleFinance.com) - UBS today downgrades its Fresenius Medical Care shares from "neutral" to "sell", reducing its target price for them from E43.
5 to E42, with the latter representing 12% downside potential for the German dialysis specialist.

"Consensus expects another FY23 raise, shares are near 5 year highs, and FRE deconsolidation, GLP-1 data and Marietta ruling could be overhangs," the broker says.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.